Experts will discuss potential neutralizing antibodies currently under investigation for SARS-CoV-2 treatment.

Lonza will employ more than 200 full-time staff to work at the Texas-based facility, the company says.

The biotech firm Celgene inks a huge collaboration deal with Juno Therapeutics to develop and commercialize new cancer immunotherapies.

With one US patent awarded and many other applications under consideration for the popular genome-editing technology, companies are adopting multiple strategies to navigate the complex intellectual property landscape.

Tumor-targeting T-cell therapies are generating remarkable remissions in hard-to-beat cancers—and attracting millions of dollars of investment along the way.

Now showing clinical progress against liver diseases, the gene-silencing technique begins to fulfill some of its promises.

A government lab finds a novel virus present in cell lines used for therapeutic production that were thought to be virus-free.

Clostridium difficile is evolving more robust toxicity, repeatedly attacking its victims, and driving the search for alternative therapies to fight the infection.